Patisiran: Mechanism of Action
The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.
The full Prescribing Information for ONPATTRO® (patisiran) is provided here. Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.
If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.
SUMMARY |
- RNAi is a natural endogenous intracellular catalytic mechanism for the control of gene expression that utilizes siRNAs loaded onto the cytoplasmic RISC to cleave and degrade specific mRNA targets through AGO2, the catalytic component of the RISC. This results in reduced production of the target protein.1–3
- Patisiran is a double-stranded siRNA, formulated as a lipid complex for delivery to hepatocytes. It specifically binds to a genetically conserved sequence in the 3’ UTR of mutant and wild-type TTR mRNA. Patisiran causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.4
|
Abbreviations
3’UTR = 3’ untranslated region; AGO2 = argonaute RISC catalytic component 2; mRNA = messenger RNA; RISC = RNA-induced silencing complex; RNA = ribonucleic acid; RNAi = RNA interference; siRNA = small interfering ribonucleic acid; TTR = transthyretin.
Updated 3 December 2024
References
1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494-498. doi:10.1038/35078107
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811. doi:10.1038/35888
3. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67(4):657-685. doi:10.1128/MMBR.67.4.657-685.2003
4. ONPATTRO (patisiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
| | |
MED-US-TTR02-1800599 6.0 Approved through Dec 2026 |
